A Phase 2, Multicenter, Single Arm, Open Label, Non-Randomized Study of [18F]FAPI-74 PET in Patients with Gastrointestinal Cancers
Latest Information Update: 04 Mar 2025
At a glance
- Drugs 18-F FAPI 74 (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer
- Focus Diagnostic use
- Acronyms 18F-FAPI-74 GI
- Sponsors SOFIE
- 25 Feb 2025 Planned primary completion date changed from 31 Jul 2024 to 28 Feb 2025.
- 12 May 2023 According to a SOFIE media release, first patient has been dosed and imaged.
- 11 May 2023 Status changed from not yet recruiting to recruiting.